These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Should patients with pulmonary hypertension and increased pulmonary resistance be treated with vasodilators? Rich S Cardiovasc Clin; 1990; 21(1):265-74; discussion 275-6. PubMed ID: 2199052 [No Abstract] [Full Text] [Related]
6. Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension. Guazzi M; Gomberg-Maitland M; Naeije R Prog Cardiovasc Dis; 2015; 57(5):473-9. PubMed ID: 25446553 [TBL] [Abstract][Full Text] [Related]
7. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428 [TBL] [Abstract][Full Text] [Related]
8. [Pulmonary hypertension of the newborn - mechanisms of failed circulatory adaptation after birth, clinical presentation and diagnosis]. Vakrilova L Akush Ginekol (Sofiia); 2014; 53(3):34-40. PubMed ID: 25509644 [TBL] [Abstract][Full Text] [Related]
11. Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension. Blaukovitsch M; Zabel P; Hauber HP Recent Pat Cardiovasc Drug Discov; 2009 Jun; 4(2):142-9. PubMed ID: 19519556 [TBL] [Abstract][Full Text] [Related]
12. [Primary pulmonary hypertension and its management]. Crespo Martínez C; Morales León V; Alonso Ramos H; Alonso Ortiz B; Molero Gómez R Farm Hosp; 2004; 28(1):48-55. PubMed ID: 15012178 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Klinger JR; Abman SH; Gladwin MT Am J Respir Crit Care Med; 2013 Sep; 188(6):639-46. PubMed ID: 23822809 [TBL] [Abstract][Full Text] [Related]
14. Role of the endothelium in pulmonary arterial hypertension. Haworth SG Vascul Pharmacol; 2006 Nov; 45(5):317-25. PubMed ID: 17005453 [TBL] [Abstract][Full Text] [Related]
15. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Agarwal R; Gomberg-Maitland M Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension. Gray EA; Tsuchimochi H; Pearson JT; Sonobe T; Fujii Y; Yoshimoto M; Umetani K; Shirai M; Schwenke DO J Synchrotron Radiat; 2013 Sep; 20(Pt 5):756-64. PubMed ID: 23955040 [TBL] [Abstract][Full Text] [Related]
17. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Rubin LJ Am J Respir Crit Care Med; 2002 Nov; 166(10):1308-9. PubMed ID: 12421739 [No Abstract] [Full Text] [Related]
18. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Lahm T; Crisostomo PR; Markel TA; Wang M; Lillemoe KD; Meldrum DR Shock; 2007 Jul; 28(1):4-14. PubMed ID: 17510598 [TBL] [Abstract][Full Text] [Related]
19. Pathology and pathobiology of pulmonary hypertension. Guignabert C; Dorfmuller P Semin Respir Crit Care Med; 2013 Oct; 34(5):551-9. PubMed ID: 24037624 [TBL] [Abstract][Full Text] [Related]